All In MedTech

Device Trial Radar · NCT03894033

Post-market Registry of the AMDS for the Treatment of Acute DeBakey Type I Dissection

Post-market Registry of the AMDS for the Treatment of Acute DeBakey Type I Dissection: PROTECT Registry

Last checked: Nov 20, 2026Latest source record: Feb 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

301

Actual

Start

Mar 12, 2019

Primary completion

Jun 30, 2026

Study completion Jun 30, 2030

Sponsor

Lead sponsor
JOTEC GmbHNot on our public-company list
Sponsor type
Industry
First posted
Mar 28, 2019

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this registry is to collect information on the performance and clinical benefits of the AMDS (Ascyrus Medical Dissection Stent) to treat patients with acute "DeBakey type I dissections" and with or without so called "preoperative clinically relevant malperfusion" and/or "intramural hematomas". In a healthy aorta (the vessel that supplies blood to most of the body) the blood flows freely through the main lumen (a space inside the vessel where blood flows). The participants involved in this study have a tear that has separated the inner layer of the aorta wall and created a secondary channel (false lumen) in addition to the main channel (true lumen), and huts, the blood flows through both channels. AMDS is a stent (a metal tube helping to keep the vessel open) that is placed in the descending thoracic aorta. AMDS is a medical device commercially available in the countries in which the study is being conducted and it is used as standard of care according to its indication.

Conditions

  • Aortic Dissection
  • Acute DeBakey I Dissection
  • Acute Type A Dissection
  • Intramural Hematoma

Interventions

  • Ascyrus Medical Dissection Stent (AMDS)Device

    The device will be implanted during already planned surgical intervention for aortic dissection repair. The participant will be observed and data gathered during the surgery and routine standard of care follow up visits.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Positive arch remodelingTime frame: 3-6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Deutsches Herzzentrum der Charité

    Berlin, State of Berlin, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.